SG11201808154XA - Use of insulin for promoting gastric emptying - Google Patents
Use of insulin for promoting gastric emptyingInfo
- Publication number
- SG11201808154XA SG11201808154XA SG11201808154XA SG11201808154XA SG11201808154XA SG 11201808154X A SG11201808154X A SG 11201808154XA SG 11201808154X A SG11201808154X A SG 11201808154XA SG 11201808154X A SG11201808154X A SG 11201808154XA SG 11201808154X A SG11201808154X A SG 11201808154XA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- gastric emptying
- insulin
- pct
- promoting gastric
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 8
- 102000004877 Insulin Human genes 0.000 title abstract 4
- 108090001061 Insulin Proteins 0.000 title abstract 4
- 230000030136 gastric emptying Effects 0.000 title abstract 4
- 229940125396 insulin Drugs 0.000 title abstract 4
- 230000001737 promoting effect Effects 0.000 title abstract 4
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 206010021518 Impaired gastric emptying Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Physiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Inorganic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662312473P | 2016-03-24 | 2016-03-24 | |
| PCT/US2017/024053 WO2017165789A1 (en) | 2016-03-24 | 2017-03-24 | Use of insulin for promoting gastric emptying |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201808154XA true SG11201808154XA (en) | 2018-10-30 |
Family
ID=59900798
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201808154XA SG11201808154XA (en) | 2016-03-24 | 2017-03-24 | Use of insulin for promoting gastric emptying |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US10046032B2 (zh) |
| EP (1) | EP3432861B1 (zh) |
| JP (1) | JP7102347B2 (zh) |
| KR (1) | KR20180123114A (zh) |
| CN (1) | CN109152733A (zh) |
| AR (1) | AR108753A1 (zh) |
| AU (1) | AU2017237164A1 (zh) |
| BR (1) | BR112018069444A2 (zh) |
| CA (1) | CA3018215C (zh) |
| ES (1) | ES2957891T3 (zh) |
| HR (1) | HRP20230972T1 (zh) |
| HU (1) | HUE062950T2 (zh) |
| IL (1) | IL261898A (zh) |
| MX (1) | MX2018011512A (zh) |
| PL (1) | PL3432861T3 (zh) |
| RS (1) | RS64623B1 (zh) |
| RU (1) | RU2018133604A (zh) |
| SG (1) | SG11201808154XA (zh) |
| WO (1) | WO2017165789A1 (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017237164A1 (en) | 2016-03-24 | 2018-10-11 | Nutrinia Ltd. | Use of insulin for promoting gastric emptying |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5356625A (en) | 1986-08-28 | 1994-10-18 | Enzacor Properties Limited | Microgranular preparation useful in the delivery of biologically active materials to the intestinal regions of animals |
| DE3789965T2 (de) | 1986-08-28 | 1994-10-13 | Enzacor Pty Ltd | Mikrogranuläre zubereitung zur verabreichung biologisch aktiver stoffe in den eingeweideregionen von tieren. |
| FR2606597B1 (fr) | 1986-11-17 | 1989-01-27 | Rhone Poulenc Sante | Nouvelle composition pour l'alimentation des ruminants contenant une substance biologiquement active et sa preparation |
| US4944944A (en) | 1987-11-19 | 1990-07-31 | Oklahoma Medical Research Foundation | Dietary compositions and methods using bile salt-activated lipase |
| US5013569A (en) | 1990-05-21 | 1991-05-07 | Century Laboratories, Inc. | Infant formula |
| US5418010A (en) | 1990-10-05 | 1995-05-23 | Griffith Laboratories Worldwide, Inc. | Microencapsulation process |
| DE4100920A1 (de) | 1991-01-15 | 1992-07-16 | Degussa | Wirkstoffzubereitung zur oralen verabreichung an wiederkaeuer |
| US5160742A (en) | 1991-12-31 | 1992-11-03 | Abbott Laboratories | System for delivering an active substance for sustained release |
| US5360614A (en) | 1993-04-26 | 1994-11-01 | The Estee Corporation | Method of controlling the release of carbohydrates by encapsulation and composition therefor |
| US5405637A (en) | 1993-06-30 | 1995-04-11 | Bristol-Myers Squibb Company | Milk protein partial hydrolysate and infant formula containing same |
| US5531989A (en) | 1994-10-28 | 1996-07-02 | Metagenics, Inc. | Immunoglobulin and fiber-containing composition for human gastrointestinal health |
| ATE207312T1 (de) | 1995-06-29 | 2001-11-15 | Nestle Sa | Verfahren zur verkapselung eines kernmaterials mit einem polymer durch hochdruckbehandlung |
| JPH10155428A (ja) | 1996-12-04 | 1998-06-16 | Shida Kanzume Kk | 毛づや改善剤及び毛づやの改善方法、並びに健康食品 |
| ID23411A (id) | 1997-03-27 | 2000-04-20 | Bristol Myers Squibb Co | Penggunaan asam dokosaheksanoat dan asam arakidonat yang meningkatkan pertumbuhan bayi belum cukup bulan |
| JPH119196A (ja) | 1997-06-24 | 1999-01-19 | Meiji Seika Kaisha Ltd | キトサンによる家畜の損耗防止の方法 |
| TR199901008T1 (xx) | 1997-09-09 | 2000-02-21 | Select Release, L.C. | Kaplanm�� partik�ller, yap�m� ve kullan�m y�ntemleri. |
| US6638621B2 (en) | 2000-08-16 | 2003-10-28 | Lyotropic Therapeutics, Inc. | Coated particles, methods of making and using |
| US6399090B1 (en) | 1998-06-05 | 2002-06-04 | Insotech Ltd. | Insulin supplemented infant formula |
| ATE413889T1 (de) | 1998-06-05 | 2008-11-15 | Nutrinia Ltd | Insulin angereichertes säuglingsnährpräparat |
| JP2000050793A (ja) | 1998-08-07 | 2000-02-22 | Meiji Milk Prod Co Ltd | 人工乳組成物 |
| JP2000116320A (ja) | 1998-10-13 | 2000-04-25 | Bingu Gure:Kk | 乳酸菌カプセル入りヨーグルト及びその製造方法 |
| GB2345836A (en) | 1999-01-25 | 2000-07-26 | Charleville Res | Animal milk replacer |
| US7374779B2 (en) | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
| US6548043B1 (en) | 1999-08-03 | 2003-04-15 | Metabolic Solutions, Inc. | Measurement of gastric emptying |
| US6774128B2 (en) | 2000-04-19 | 2004-08-10 | Johns Hopkins University | Methods for prevention and treatment of gastrointestinal disorders |
| CN100396769C (zh) | 2000-05-25 | 2008-06-25 | 雀巢制品公司 | 宠物食物使用的新益生菌 |
| EP1214892B1 (en) | 2000-12-15 | 2005-03-09 | Quest International B.V. | A moisture and oxygen stable composition and a process for obtaining said composition |
| JP2002209513A (ja) | 2000-12-15 | 2002-07-30 | Bingu-Gure:Kk | 栄養成分を含有する多数のカプセル入り強化牛乳 |
| AUPR272901A0 (en) | 2001-01-25 | 2001-02-22 | Gainful Plan Limited | Method of preparing biological materials and preparations produced using same |
| CN1531399A (zh) | 2001-05-14 | 2004-09-22 | 瓦西里・彼得罗维奇・安德烈丘克 | 预防碘缺乏和优化碘代谢的生物活性食品添加剂和生物活性饲料添加剂,以及含该添加剂的食品和饲料 |
| US20050226905A1 (en) | 2001-05-22 | 2005-10-13 | Tien Canh L | Biocompatible compositions as carriers or excipients for pharmaceutical and nutraceutical formulations and for food protection |
| US20030044458A1 (en) | 2001-08-06 | 2003-03-06 | Curtis Wright | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
| US6951655B2 (en) | 2001-10-11 | 2005-10-04 | Imi Biomed, Inc. | Pro-micelle pharmaceutical compositions |
| US20030175403A1 (en) | 2002-03-14 | 2003-09-18 | Gurin Michael H. | Potentiated bioactive additives and method of use |
| US20030175382A1 (en) | 2002-03-14 | 2003-09-18 | Dally Vernetta L. | Heat released encapsulated yeast |
| CN1656205A (zh) | 2002-07-01 | 2005-08-17 | 诺和酶股份有限公司 | 颗粒的稳定 |
| US6835397B2 (en) | 2002-12-23 | 2004-12-28 | Balchem Corporation | Controlled release encapsulated bioactive substances |
| US8877232B2 (en) | 2003-06-20 | 2014-11-04 | Nutrinia Ltd. | Bioactive compounds protection method and compositions containing the same |
| WO2005115473A2 (en) | 2004-05-24 | 2005-12-08 | Nutrinia Ltd. | Nutritional food and feed, composition, processing and method of use |
| US8026211B2 (en) | 2004-06-02 | 2011-09-27 | Technion Research & Development Foundation Ltd. | Methods and formulations for increasing intestinal function |
| GB0502795D0 (en) | 2005-02-10 | 2005-03-16 | Univ Cambridge Tech | Treatment of very low birthweight (vlbw) infants |
| CA2621577C (en) | 2005-09-06 | 2013-12-24 | Oramed Pharmaceuticals, Inc. | Methods and compositions for oral administration of proteins |
| AU2008259372B2 (en) | 2007-06-07 | 2014-07-10 | Elgan Pharma Ltd | Means and methods for enhancing weight gain in poultry |
| US7943733B2 (en) | 2007-12-20 | 2011-05-17 | University Of Southern California | Spacers to increase the expression of recombinant fusion proteins |
| ES2603328T3 (es) | 2010-10-21 | 2017-02-27 | Swedish Orphan Biovitrum Ab (Publ) | Método para incrementar la tasa de crecimiento de lactantes humanos |
| EP2520298A1 (en) | 2011-05-03 | 2012-11-07 | Assistance Publique, Hopitaux De Paris | Pharmaceutical composition comprising sulfonylureas (glibenclamide) or meglitinides for use for treating hyperglycaemia or for promoting growth of a premature infant |
| CA2870091A1 (en) | 2012-04-18 | 2013-10-24 | Nutrinia Ltd. | Growth enhancement of infants |
| US20150209412A1 (en) | 2012-05-31 | 2015-07-30 | Nutrinia Ltd. | Insulin-containing infant formula |
| AU2017237164A1 (en) | 2016-03-24 | 2018-10-11 | Nutrinia Ltd. | Use of insulin for promoting gastric emptying |
-
2017
- 2017-03-24 AU AU2017237164A patent/AU2017237164A1/en not_active Abandoned
- 2017-03-24 KR KR1020187029772A patent/KR20180123114A/ko not_active IP Right Cessation
- 2017-03-24 US US15/468,965 patent/US10046032B2/en active Active
- 2017-03-24 RU RU2018133604A patent/RU2018133604A/ru not_active Application Discontinuation
- 2017-03-24 HU HUE17771247A patent/HUE062950T2/hu unknown
- 2017-03-24 EP EP17771247.8A patent/EP3432861B1/en active Active
- 2017-03-24 ES ES17771247T patent/ES2957891T3/es active Active
- 2017-03-24 WO PCT/US2017/024053 patent/WO2017165789A1/en active Application Filing
- 2017-03-24 HR HRP20230972TT patent/HRP20230972T1/hr unknown
- 2017-03-24 RS RS20230856A patent/RS64623B1/sr unknown
- 2017-03-24 JP JP2018549878A patent/JP7102347B2/ja active Active
- 2017-03-24 CA CA3018215A patent/CA3018215C/en active Active
- 2017-03-24 SG SG11201808154XA patent/SG11201808154XA/en unknown
- 2017-03-24 PL PL17771247.8T patent/PL3432861T3/pl unknown
- 2017-03-24 MX MX2018011512A patent/MX2018011512A/es unknown
- 2017-03-24 CN CN201780030498.8A patent/CN109152733A/zh active Pending
- 2017-03-24 BR BR112018069444A patent/BR112018069444A2/pt not_active Application Discontinuation
- 2017-03-27 AR ARP170100743A patent/AR108753A1/es unknown
-
2018
- 2018-09-20 IL IL261898A patent/IL261898A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017237164A1 (en) | 2018-10-11 |
| RS64623B1 (sr) | 2023-10-31 |
| JP2019509317A (ja) | 2019-04-04 |
| US10046032B2 (en) | 2018-08-14 |
| EP3432861C0 (en) | 2023-07-12 |
| ES2957891T3 (es) | 2024-01-29 |
| PL3432861T3 (pl) | 2023-12-18 |
| US20170319663A1 (en) | 2017-11-09 |
| EP3432861A4 (en) | 2019-10-23 |
| CA3018215A1 (en) | 2017-09-28 |
| BR112018069444A2 (pt) | 2019-10-08 |
| JP7102347B2 (ja) | 2022-07-19 |
| MX2018011512A (es) | 2019-02-07 |
| CA3018215C (en) | 2023-10-03 |
| HRP20230972T1 (hr) | 2023-12-08 |
| EP3432861A1 (en) | 2019-01-30 |
| RU2018133604A (ru) | 2020-04-24 |
| IL261898A (en) | 2018-10-31 |
| WO2017165789A1 (en) | 2017-09-28 |
| EP3432861B1 (en) | 2023-07-12 |
| HUE062950T2 (hu) | 2023-12-28 |
| AR108753A1 (es) | 2018-09-26 |
| CN109152733A (zh) | 2019-01-04 |
| KR20180123114A (ko) | 2018-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201806624XA (en) | Deposition of molybdenum thin films using a molybdenum carbonyl precursor | |
| SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201908820VA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201811491YA (en) | Quinazoline and indole compounds to treat medical disorders | |
| SG11201807176XA (en) | TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201910134SA (en) | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201807720TA (en) | Methods and systems for determining antibiotic susceptibility | |
| SG11201407417VA (en) | Encoding and reconstruction of residual data based on support information | |
| SG11201900349VA (en) | Somatostatin modulators and uses thereof | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
| SG11201804673WA (en) | Novel anti-claudin antibodies and methods of use | |
| SG11201407655TA (en) | Therapeutic uses of fibroblast growth factor 21 proteins | |
| SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201408228QA (en) | Dual receptor antagonistic antigen-binding proteins and uses thereof | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201803816RA (en) | Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease | |
| SG11201809531SA (en) | BINDING MOLECULES SPECIFIC FOR FCγGAMMA RIIA AND USES THEREOF |